CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
Intensive Care Medicine Experimental, 2020 Background 3,4-Methylenedioxymethamphetamine intoxication can result in potentially lethal multi-organ failure, for which the current treatment is largely supportive.
Patrick M. Honore +2 more
doaj +2 more sources
CytoSorb in Patients With Coronavirus Disease 2019: A Rapid Evidence Review and Meta-Analysis
Frontiers in Immunology, 2023 BackgroundAfter its approval by the European Union in 2011, CytoSorb therapy has been applied to control cytokine storm and lower the increased levels of cytokines and other inflammatory mediators in blood.
Yongnan Li, Yanchun Zhang
exaly +3 more sources
Antibiotics and Other Drugs Removal by the CytoSorb® Haemoadsorber: A Systematic Review of Available Evidence [PDF]
AntibioticsBackground/Objectives: Haemoadsorption has recently emerged as an extracorporeal treatment option for sepsis, septic shock, intoxications, and cardiac surgery to modulate dysregulated inflammatory responses or remove a wide range of circulating molecules.
Sara Kenda, Jakob Gubenšek, Tomaž Vovk
doaj +2 more sources
Biomedicines, 2020 Septic shock is a major burden to healthcare with mortality rates remaining high. Blood purification techniques aim to reduce cytokine levels and resultant organ failure.
Janett Kreutziger +2 more
exaly +3 more sources
Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study [PDF]
Critical Care, 2019 Background and aims Innovative treatment modalities have not yet shown a clinical benefit in patients with septic shock. To reduce severe cytokinaemia, CytoSorb as an add-on to continuous renal replacement therapy (CRRT) showed promising results in case ...
Willem Pieter Brouwer +3 more
doaj +2 more sources
Early impact of CytoSorb® adsorber on proinflammatory cytokine plasmatic levels in a porcine model of refractory cardiogenic shock supported with VA-ECMO [PDF]
BMC Cardiovascular DisordersBackground Cardiogenic shock (CS) is a pejorative situation which often requires a circulatory support with VA-ECMO. However, VA-ECMO is known to trigger an inflammatory cascade with expression of proinflammatory cytokines Interleukin-6 (IL-6) and ...
Juliette Piccoli +9 more
doaj +2 more sources
Frontiers in Medicine, 2021 Introduction: CytoSorb extracorporeal blood purification therapy received FDA Emergency Use Authorization (EUA) to suppress hyperinflammation in critically ill COVID-19 patients.
Lucian A Durham +2 more
exaly +3 more sources
Hemadsorption with Adult CytoSorb® in a Low Weight Pediatric Case [PDF]
Case Reports in Critical Care, 2017 Cytokine adsorber (CytoSorb) has been used successfully as adjunctive treatment for adult patients with elevated cytokine levels in the setting with severe sepsis and septic shock and to reduce blood myoglobin, unconjugated bilirubin, and conjugated bilirubin.
Catalin Gabriel Cirstoveanu +2 more
openaire +4 more sources
A single centre experience with CytoSorb® as an adjunct therapy in critically ill patients with sepsis: a case series [PDF]
International Journal of Medical Device and Adjuvant Treatments, 2023 Objective: Sepsis is an immune response to infections that are caused by bacteria, viruses, fungi, or parasites. This potentially life-threatening condition is associated with high mortality and morbidity that causes a major global health burden and ...
H. Gajera, S. Gohil, A. Chhatravala
doaj +3 more sources
Hemadsorption with CytoSorb in Infants with Sepsis: Non-Systematic Review of Cases
Journal of Clinical MedicineSepsis is a severe and potentially life-threatening condition that occurs when the body’s response to an infection damages its own tissues and organs. It can lead to organ failure and death if not treated. Cytosorb is a promising medical device for hemadsorption in pediatric septic patients (under 18 years old).
Aruzhan Borankulova, Vitaliy Sazonov
openaire +3 more sources